The Serum Metabolomics Study of Liver Failure and Artificial Liver Therapy Intervention

15 October 2021: Clinical Research

Shipeng Huang ^1ABC , Dali Hu ^2BCD , Songsong Yuan ^2BCD , Ying He ^2BCD , Chengmu Li ^2BCD , Ying Zhu ^2BCD , Xiaoping Wu ^2AEF*

DOI: 10.12659/MSM.930638

Med Sci Monit 2021; 27:e930638

Table 1 General data and clinical characteristics of the patients.

	Healthy control group (n=32)	Liver failure group (n=50)	Chronic hepatitis group (n=30)	Liver failure artificial liver therapy group (n=11)	Pa	Pb	Pc	P
MF	15/17	23/27	14/16	7/4	0.991	0.938	0.954	0.987
Age (years)	44.3±5.5	44.5±12.2	43.5±3.9	46.7±4.6	0.884	0.938	0.631	0.710
ALT (U/L)	27.6±23.8	773.2±768.2	83.3±36.7	676.6±699.3				0.666
AST (U/L)	25.3±11.5	440.0±420.0	48.3±25.4	501.8±503.6				0.745
TBiL (umol/L)	12.1±5.7	278.5±131.7	14.1±5.9	297.0±152.3				0.929
ALB (g/L)	43.4±2.9	35.9±20.8	46.2±3.2	30.4±4.1	0.004	0.018	0.002	0.433
The results were expressed as mean±standard deviation. Pa – liver failure group vs healthy control group; Pb – liver failure group vs chronic hepatitis group; Pc – chronic hepatitis group vs healthy control group; P – liver failure artificial liver therapy group vs liver failure group. P